voltage-gated Na+ channel subunit inhibitor (AstraZeneca)

N/A

Report date: 2025/01/26 15:58:03

NME

Base Information

Drug Namevoltage-gated Na+ channel subunit inhibitor (AstraZeneca)

Drug Alias NameNav1.7 inhibitor (AstraZeneca)phenyl isoxazole voltage-gated Na+ channel blockers (AstraZeneca)voltage-gated Na+ channel subunit alpha inhibitor (AstraZeneca)AZ-1297442

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionSodium channel protein type IX alpha subunit blockers

TargetsSodium channel protein type IX alpha subunit

Therapy Area/IndicationsPainCough

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySwedenUnited Kingdom

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAstrazeneca Plc

China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca Plc

Inactive CompaniesN/A

Active IndicationsCough

Inactive IndicationsPain

Other Information

ATC CodeN/A